JP2011521968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521968A5 JP2011521968A5 JP2011511842A JP2011511842A JP2011521968A5 JP 2011521968 A5 JP2011521968 A5 JP 2011521968A5 JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011521968 A5 JP2011521968 A5 JP 2011521968A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- purin
- morpholino
- methyl
- aminopyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- -1 4- (methylsulfonyl) piperazin-1-yl Chemical group 0.000 claims description 8
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229940095102 methyl benzoate Drugs 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010062038 Lip neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000016222 Pancreatic disease Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 208000015322 bone marrow disease Diseases 0.000 claims description 3
- 201000000220 brain stem cancer Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000006721 lip cancer Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000024691 pancreas disease Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000649 small cell carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- AOUUDIQPMYTKOI-UHFFFAOYSA-N 1-[2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]acetyl]-n-methylpiperidine-4-carboxamide Chemical compound C1CC(C(=O)NC)CCN1C(=O)CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 AOUUDIQPMYTKOI-UHFFFAOYSA-N 0.000 claims description 2
- HKSCZWCKMLMLDU-UHFFFAOYSA-N 1-[3-[[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]methyl]pyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 HKSCZWCKMLMLDU-UHFFFAOYSA-N 0.000 claims description 2
- AGDHHJRWRSOCAF-UHFFFAOYSA-N 1-[4-[[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]methyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 AGDHHJRWRSOCAF-UHFFFAOYSA-N 0.000 claims description 2
- MJKNDQVAWMECBQ-UHFFFAOYSA-N 2-[2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound CC1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=C(N2CCO)C(C)(C)O)C2=N1 MJKNDQVAWMECBQ-UHFFFAOYSA-N 0.000 claims description 2
- KQNBNJOVKJOMDH-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-propylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCC)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 KQNBNJOVKJOMDH-UHFFFAOYSA-N 0.000 claims description 2
- GFRPGDSXDPEGMV-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-(4-methylsulfonylpiperazin-1-yl)ethanone Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 GFRPGDSXDPEGMV-UHFFFAOYSA-N 0.000 claims description 2
- QQDUFKGDCXYVHR-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-morpholin-4-ylethanone Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CC(=O)N3CCOCC3)C2=N1 QQDUFKGDCXYVHR-UHFFFAOYSA-N 0.000 claims description 2
- AJVDFTWUNKUSJU-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]acetic acid Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CC(O)=O)C2=N1 AJVDFTWUNKUSJU-UHFFFAOYSA-N 0.000 claims description 2
- HDTHTJYWODPMJO-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]ethanol Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCO)C2=N1 HDTHTJYWODPMJO-UHFFFAOYSA-N 0.000 claims description 2
- FDDKQQRYIKXUCV-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCO)C(C(C)(O)C)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 FDDKQQRYIKXUCV-UHFFFAOYSA-N 0.000 claims description 2
- KPLJRUFOHIXWBX-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-(3-hydroxypropyl)-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCCO)C(C(C)(O)C)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 KPLJRUFOHIXWBX-UHFFFAOYSA-N 0.000 claims description 2
- QJGFOGJKIDPKSZ-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-butyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(CCCC)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 QJGFOGJKIDPKSZ-UHFFFAOYSA-N 0.000 claims description 2
- YWTFMRUDEJHZGF-UHFFFAOYSA-N 2-[2-(2-aminopyrimidin-5-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(C)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 YWTFMRUDEJHZGF-UHFFFAOYSA-N 0.000 claims description 2
- XCEDXQNTFRMXPP-UHFFFAOYSA-N 2-[2-(6-aminopyridin-3-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C2N(C)C(C(C)(C)O)=NC2=C(N2CCOCC2)N=C1C1=CC=C(N)N=C1 XCEDXQNTFRMXPP-UHFFFAOYSA-N 0.000 claims description 2
- NMTMVOGZGOVEJE-UHFFFAOYSA-N 2-[4-[[2-(2-amino-4-methylpyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperazin-1-yl]-2-methylpropanamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN1CCN(C(C)(C)C(N)=O)CC1 NMTMVOGZGOVEJE-UHFFFAOYSA-N 0.000 claims description 2
- NITGMBBDIUJMRW-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-(4-methylsulfonylpiperazin-1-yl)propan-1-one Chemical compound C1CN(S(=O)(=O)C)CCN1C(=O)CCN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 NITGMBBDIUJMRW-UHFFFAOYSA-N 0.000 claims description 2
- NGECFAVNFYGEQO-CQSZACIVSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-[(3r)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(=O)N3C[C@H](O)CC3)C2=N1 NGECFAVNFYGEQO-CQSZACIVSA-N 0.000 claims description 2
- NGECFAVNFYGEQO-AWEZNQCLSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-[(3s)-3-hydroxypyrrolidin-1-yl]propan-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(=O)N3C[C@@H](O)CC3)C2=N1 NGECFAVNFYGEQO-AWEZNQCLSA-N 0.000 claims description 2
- KPZTWHKISNKFTP-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]-1-morpholin-4-ylpropan-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(=O)N3CCOCC3)C2=N1 KPZTWHKISNKFTP-UHFFFAOYSA-N 0.000 claims description 2
- XHGAULXLKKZIQP-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]propan-1-ol Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCCO)C2=N1 XHGAULXLKKZIQP-UHFFFAOYSA-N 0.000 claims description 2
- CODFKSZBVMZBRH-UHFFFAOYSA-N 3-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-ylpurin-9-yl]propanoic acid Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCC(O)=O)C2=N1 CODFKSZBVMZBRH-UHFFFAOYSA-N 0.000 claims description 2
- MAXIMYAATWVVQK-UHFFFAOYSA-N 4-[2-(2-methoxypyrimidin-5-yl)-9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]purin-6-yl]morpholine Chemical compound C1=NC(OC)=NC=C1C1=NC(N2CCOCC2)=C(N=C(CN2CCN(CC2)S(C)(=O)=O)N2C)C2=N1 MAXIMYAATWVVQK-UHFFFAOYSA-N 0.000 claims description 2
- XLONKHTYYXTLNL-UHFFFAOYSA-N 4-[9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]-2-pyridin-3-ylpurin-6-yl]morpholine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC=CC=3)N=C2N(C)C=1CN1CCN(S(C)(=O)=O)CC1 XLONKHTYYXTLNL-UHFFFAOYSA-N 0.000 claims description 2
- MELXZZULKDAPHV-UHFFFAOYSA-N 5-(9-methyl-6-morpholin-4-ylpurin-2-yl)pyridin-2-amine Chemical compound N1=C2N(C)C=NC2=C(N2CCOCC2)N=C1C1=CC=C(N)N=C1 MELXZZULKDAPHV-UHFFFAOYSA-N 0.000 claims description 2
- OGLQNIWTBCUNNG-UHFFFAOYSA-N 5-(9-methyl-6-morpholin-4-ylpurin-2-yl)pyrimidin-2-amine Chemical compound N1=C2N(C)C=NC2=C(N2CCOCC2)N=C1C1=CN=C(N)N=C1 OGLQNIWTBCUNNG-UHFFFAOYSA-N 0.000 claims description 2
- RDSWHFASXQEXJX-UHFFFAOYSA-N 5-[6-morpholin-4-yl-9-(2-morpholin-4-ylethyl)purin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CCOCC2)=C(N=CN2CCN3CCOCC3)C2=N1 RDSWHFASXQEXJX-UHFFFAOYSA-N 0.000 claims description 2
- NMSXNXUCMSOCQX-UHFFFAOYSA-N 5-[8-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-9-ethyl-6-morpholin-4-ylpurin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN(CC1)CCC1N1CCC1 NMSXNXUCMSOCQX-UHFFFAOYSA-N 0.000 claims description 2
- RHXUXGFENWIZLX-UHFFFAOYSA-N 5-[8-[[4-(azetidin-1-yl)piperidin-1-yl]methyl]-9-ethyl-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN(CC1)CCC1N1CCC1 RHXUXGFENWIZLX-UHFFFAOYSA-N 0.000 claims description 2
- QJQGJTVWYYKZAF-UHFFFAOYSA-N 5-[8-[[4-(dimethylamino)piperidin-1-yl]methyl]-9-ethyl-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN1CCC(N(C)C)CC1 QJQGJTVWYYKZAF-UHFFFAOYSA-N 0.000 claims description 2
- DTUURQKCKMPNGR-UHFFFAOYSA-N 5-[9-[(3-methoxyphenyl)methyl]-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound COC1=CC=CC(CN2C3=NC(=NC(=C3N=C2)N2CCOCC2)C=2C=NC(N)=NC=2)=C1 DTUURQKCKMPNGR-UHFFFAOYSA-N 0.000 claims description 2
- KAPWFCMMNVOORR-UHFFFAOYSA-N 5-[9-[(4-methylsulfonylphenyl)methyl]-6-morpholin-4-ylpurin-2-yl]pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CN1C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2N=C1 KAPWFCMMNVOORR-UHFFFAOYSA-N 0.000 claims description 2
- TUCAPDBFAOJHOT-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-morpholin-4-ylpiperidin-1-yl)methyl]purin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN(CC1)CCC1N1CCOCC1 TUCAPDBFAOJHOT-UHFFFAOYSA-N 0.000 claims description 2
- BHQMKXSPJSCTDH-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-morpholin-4-ylpiperidin-1-yl)methyl]purin-2-yl]pyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN(CC1)CCC1N1CCOCC1 BHQMKXSPJSCTDH-UHFFFAOYSA-N 0.000 claims description 2
- FPQFBQMNHUKFDS-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-piperidin-1-ylpiperidin-1-yl)methyl]purin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN(CC1)CCC1N1CCCCC1 FPQFBQMNHUKFDS-UHFFFAOYSA-N 0.000 claims description 2
- VTAHIFPHJDMNQT-UHFFFAOYSA-N 5-[9-ethyl-6-morpholin-4-yl-8-[(4-piperidin-1-ylpiperidin-1-yl)methyl]purin-2-yl]pyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN(CC1)CCC1N1CCCCC1 VTAHIFPHJDMNQT-UHFFFAOYSA-N 0.000 claims description 2
- KWVCMUVZXMIWLA-UHFFFAOYSA-N 5-[9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]-6-morpholin-4-ylpurin-2-yl]pyridin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=CC=3)N=C2N(C)C=1CN1CCN(S(C)(=O)=O)CC1 KWVCMUVZXMIWLA-UHFFFAOYSA-N 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- OJXQQSGPFJPLCE-UHFFFAOYSA-N CC(C(=O)C1CNCCC1C(=O)NC)N2C=NC3=C2N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N Chemical compound CC(C(=O)C1CNCCC1C(=O)NC)N2C=NC3=C2N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N OJXQQSGPFJPLCE-UHFFFAOYSA-N 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- WHRNQECLXDEWAY-UHFFFAOYSA-N n-[1-[[2-(2-amino-4-methylpyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperidin-4-yl]-n-methylmethanesulfonamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN1CCC(N(C)S(C)(=O)=O)CC1 WHRNQECLXDEWAY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000003780 keratinization Effects 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- KSQHFCOCMGKFHC-UHFFFAOYSA-N n-[1-[[2-(2-aminopyrimidin-5-yl)-9-ethyl-6-morpholin-4-ylpurin-8-yl]methyl]piperidin-4-yl]-n-methylmethanesulfonamide Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N(CC)C=1CN1CCC(N(C)S(C)(=O)=O)CC1 KSQHFCOCMGKFHC-UHFFFAOYSA-N 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- XHVHZFXNUIYBBO-UHFFFAOYSA-N 2-[2-(1h-indazol-4-yl)-9-methyl-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2N(C)C(C(C)(C)O)=NC2=C1N1CCOCC1 XHVHZFXNUIYBBO-UHFFFAOYSA-N 0.000 description 1
- LWQWJNNUZUSBMF-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)-6-morpholin-4-ylpurin-9-yl]-n-methylacetamide Chemical compound N1=C2N(CC(=O)NC)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 LWQWJNNUZUSBMF-UHFFFAOYSA-N 0.000 description 1
- QUVMETYUBXOTMG-UHFFFAOYSA-N 2-[9-(2-hydroxyethyl)-2-(1h-indol-4-yl)-6-morpholin-4-ylpurin-8-yl]propan-2-ol Chemical compound N1=C(C=2C=3C=CNC=3C=CC=2)N=C2N(CCO)C(C(C)(O)C)=NC2=C1N1CCOCC1 QUVMETYUBXOTMG-UHFFFAOYSA-N 0.000 description 1
- GRGVZPAJQCAWAX-UHFFFAOYSA-N 3-(9-benzyl-6-morpholin-4-ylpurin-2-yl)phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CC=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 GRGVZPAJQCAWAX-UHFFFAOYSA-N 0.000 description 1
- ZENYQCKYSXLZEH-UHFFFAOYSA-N 3-[6-morpholin-4-yl-9-(pyridin-4-ylmethyl)purin-2-yl]phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CN=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 ZENYQCKYSXLZEH-UHFFFAOYSA-N 0.000 description 1
- DGAMBEREUILCPV-UHFFFAOYSA-N 3-[9-(2-hydroxyethyl)-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound N1=C2N(CCO)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 DGAMBEREUILCPV-UHFFFAOYSA-N 0.000 description 1
- NDUUVXXLPJLSJB-UHFFFAOYSA-N 3-[9-(2-methylpropyl)-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound N1=C2N(CC(C)C)C=NC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 NDUUVXXLPJLSJB-UHFFFAOYSA-N 0.000 description 1
- BITPBCRAXMHMRI-UHFFFAOYSA-N 3-[9-[(4-fluorophenyl)methyl]-6-morpholin-4-ylpurin-2-yl]phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=CC(F)=CC=4)C=NC3=C(N3CCOCC3)N=2)=C1 BITPBCRAXMHMRI-UHFFFAOYSA-N 0.000 description 1
- FXEDTOMEAAGWRT-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-9-(2-methoxyethyl)-8-[(4-methylsulfonylpiperazin-1-yl)methyl]purin-6-yl]morpholine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C=4C=NNC=4C=CC=3)N=C2N(CCOC)C=1CN1CCN(S(C)(=O)=O)CC1 FXEDTOMEAAGWRT-UHFFFAOYSA-N 0.000 description 1
- BSKPTSSXGDEZDB-UHFFFAOYSA-N 4-[2-(1h-indazol-4-yl)-9-methylpurin-6-yl]morpholine Chemical compound N1=C(C=2C=3C=NNC=3C=CC=2)N=C2N(C)C=NC2=C1N1CCOCC1 BSKPTSSXGDEZDB-UHFFFAOYSA-N 0.000 description 1
- XDQBBPSIOSPKHU-UHFFFAOYSA-N 5-[8-[[4-(dimethylamino)piperidin-1-yl]methyl]-9-ethyl-6-morpholin-4-ylpurin-2-yl]-4-methylpyrimidin-2-amine Chemical compound N=1C2=C(N3CCOCC3)N=C(C=3C(=NC(N)=NC=3)C)N=C2N(CC)C=1CN1CCC(N(C)C)CC1 XDQBBPSIOSPKHU-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- BMEOUALTYJSZAF-UHFFFAOYSA-N n-[4-[9-methyl-8-[(4-methylsulfonylpiperazin-1-yl)methyl]-6-morpholin-4-ylpurin-2-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NC(N2CCOCC2)=C(N=C(CN2CCN(CC2)S(C)(=O)=O)N2C)C2=N1 BMEOUALTYJSZAF-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5755908P | 2008-05-30 | 2008-05-30 | |
| US61/057,559 | 2008-05-30 | ||
| PCT/US2009/045603 WO2009146406A1 (en) | 2008-05-30 | 2009-05-29 | Purine pi3k inhibitor compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011521968A JP2011521968A (ja) | 2011-07-28 |
| JP2011521968A5 true JP2011521968A5 (enExample) | 2012-07-12 |
Family
ID=41017038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511842A Pending JP2011521968A (ja) | 2008-05-30 | 2009-05-29 | プリンｐｉ３ｋ阻害剤化合物および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8158624B2 (enExample) |
| EP (1) | EP2279188B1 (enExample) |
| JP (1) | JP2011521968A (enExample) |
| KR (1) | KR20110042153A (enExample) |
| CN (1) | CN102105474B (enExample) |
| AU (1) | AU2009251291B2 (enExample) |
| BR (1) | BRPI0909614A2 (enExample) |
| CA (1) | CA2721851A1 (enExample) |
| ES (1) | ES2533788T3 (enExample) |
| IL (1) | IL208838A0 (enExample) |
| MX (1) | MX2010012583A (enExample) |
| RU (1) | RU2509081C2 (enExample) |
| WO (1) | WO2009146406A1 (enExample) |
| ZA (1) | ZA201007524B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2209786B1 (en) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidine substituted purine derivatives |
| JP5348725B2 (ja) * | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| US20110230464A1 (en) * | 2007-10-26 | 2011-09-22 | Paul Goldsmith | Purine derivatives useful as p13 kinase inhibitors |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| WO2010114484A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| BRPI1009022A2 (pt) * | 2009-05-27 | 2016-03-08 | Hoffmann La Roche | "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" |
| US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| JP5579864B2 (ja) * | 2009-11-12 | 2014-08-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｎ−９−置換プリン化合物、組成物及び使用の方法 |
| EP2499143B1 (en) * | 2009-11-12 | 2016-03-16 | F.Hoffmann-La Roche Ag | N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |
| CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| ES2536780T3 (es) | 2010-07-14 | 2015-05-28 | F. Hoffmann-La Roche Ag | Compuestos de purina selectivos para I3 p110 delta, y métodos de uso |
| CA2812091C (en) * | 2010-09-14 | 2020-03-24 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| TW201500358A (zh) | 2010-12-16 | 2015-01-01 | 赫夫門羅氏藥廠股份有限公司 | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| US20140298493A1 (en) * | 2011-07-28 | 2014-10-02 | Somasekar Seshagiri | PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| PT2771342T (pt) * | 2011-10-28 | 2016-08-17 | Novartis Ag | Derivados de purina e o seu uso no tratamento de doença |
| US20150011569A1 (en) * | 2011-12-15 | 2015-01-08 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20160027219A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| AU2013337717B2 (en) | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| CN103936742B (zh) * | 2013-01-17 | 2017-05-03 | 程鹏 | 含嘌呤基的新型pi3k抑制剂及其制备方法和应用 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN105209466B (zh) * | 2013-05-02 | 2018-05-18 | 豪夫迈·罗氏有限公司 | 作为cb2受体激动剂的嘌呤衍生物 |
| TW201520215A (zh) * | 2013-05-13 | 2015-06-01 | Daiichi Sankyo Co Ltd | Ｎ－□啉基嘌呤衍生物之製造方法 |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104557872B (zh) * | 2013-10-16 | 2017-05-24 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| CN103804380B (zh) * | 2014-01-24 | 2016-05-18 | 温州医科大学 | 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法 |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2015188369A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| ES2881214T3 (es) * | 2014-12-17 | 2021-11-29 | Pfizer | Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa |
| HK1250161B (en) | 2015-03-30 | 2020-05-15 | Daiichi Sankyo Company, Limited | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| US10227347B2 (en) * | 2015-04-21 | 2019-03-12 | Guizhou Bailing Group Pharmaceutical Co., Ltd. | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| US10822336B2 (en) * | 2016-09-29 | 2020-11-03 | Daiichi Sankyo Company, Limited | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof |
| ES2911522T3 (es) | 2016-12-02 | 2022-05-19 | Daiichi Sankyo Co Ltd | Novedosa endo-ß-n-acetilglucosaminidasa |
| EA202190880A1 (ru) | 2018-09-27 | 2021-06-28 | Шанхай Инли Фармасьютикал Ко., Лтд | Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение |
| AR120173A1 (es) * | 2019-10-09 | 2022-02-02 | Biocryst Pharm Inc | Inhibidores del factor d del complemento para administración oral |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| CN111875606B (zh) * | 2020-07-20 | 2023-04-07 | 武汉工程大学 | 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN116425751B (zh) * | 2022-12-19 | 2024-01-23 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的多环类化合物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016378A (en) * | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
| JPS60260579A (ja) * | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
| US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| JP2003146987A (ja) * | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| CA2460345A1 (en) * | 2001-09-13 | 2003-03-20 | Synta Pharmaceuticals Corp. | 2-aroylimidazole compounds for treating cancer |
| US6949644B2 (en) * | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
| EP1578722A4 (en) * | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| ES2279903T3 (es) * | 2001-12-18 | 2007-09-01 | Cv Therapeutics, Inc. | Antagonistas del receptor a2a de adenosina. |
| US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) * | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| JP4768265B2 (ja) * | 2002-10-15 | 2011-09-07 | シンタ ファーマシューティカルズ コーポレーション | 新規化合物 |
| WO2005000404A2 (en) * | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| TW200801012A (en) * | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20080233127A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| KR101564233B1 (ko) * | 2007-03-28 | 2015-10-29 | 뉴로서치 에이/에스 | 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도 |
| EP2144911A2 (en) | 2007-03-28 | 2010-01-20 | NeuroSearch AS | Purinyl derivatives and their use as potassium channel modulators |
| US20110230464A1 (en) * | 2007-10-26 | 2011-09-22 | Paul Goldsmith | Purine derivatives useful as p13 kinase inhibitors |
| TWI378933B (en) * | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010114484A1 (en) * | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| BRPI1009022A2 (pt) * | 2009-05-27 | 2016-03-08 | Hoffmann La Roche | "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" |
| US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| JP5579864B2 (ja) * | 2009-11-12 | 2014-08-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｎ−９−置換プリン化合物、組成物及び使用の方法 |
| ES2536780T3 (es) * | 2010-07-14 | 2015-05-28 | F. Hoffmann-La Roche Ag | Compuestos de purina selectivos para I3 p110 delta, y métodos de uso |
-
2009
- 2009-05-29 CA CA2721851A patent/CA2721851A1/en not_active Abandoned
- 2009-05-29 US US12/474,613 patent/US8158624B2/en active Active
- 2009-05-29 WO PCT/US2009/045603 patent/WO2009146406A1/en not_active Ceased
- 2009-05-29 BR BRPI0909614A patent/BRPI0909614A2/pt not_active Application Discontinuation
- 2009-05-29 JP JP2011511842A patent/JP2011521968A/ja active Pending
- 2009-05-29 MX MX2010012583A patent/MX2010012583A/es active IP Right Grant
- 2009-05-29 AU AU2009251291A patent/AU2009251291B2/en not_active Ceased
- 2009-05-29 EP EP09755767.2A patent/EP2279188B1/en active Active
- 2009-05-29 CN CN200980129148.2A patent/CN102105474B/zh active Active
- 2009-05-29 KR KR1020107026673A patent/KR20110042153A/ko not_active Ceased
- 2009-05-29 RU RU2010154428/04A patent/RU2509081C2/ru not_active IP Right Cessation
- 2009-05-29 ES ES09755767.2T patent/ES2533788T3/es active Active
-
2010
- 2010-10-20 IL IL208838A patent/IL208838A0/en unknown
- 2010-10-21 ZA ZA2010/07524A patent/ZA201007524B/en unknown
-
2012
- 2012-02-09 US US13/369,941 patent/US8445487B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521968A5 (enExample) | ||
| JP7447002B2 (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| US10287266B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| RU2010154428A (ru) | Пуриновые соединения, ингибирующие рi3к и способы применения | |
| US9815820B2 (en) | Rho kinase inhibitors | |
| JP4667537B2 (ja) | アシルチオウレア化合物又はその塩、及びその用途 | |
| KR101760651B1 (ko) | 피롤일 치환된 다이하이드로인돌 2 온 유도체, 그의 제조 방법 및 용도 | |
| JP2011510995A5 (enExample) | ||
| CA2730271A1 (en) | Pi3k isoform selective inhibitors | |
| WO2001083456A1 (en) | Condensed heteroaryl derivatives | |
| JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
| JP2009535390A5 (enExample) | ||
| WO2014151871A9 (en) | Jak2 and alk2 inhibitors and methods for their use | |
| JP6581180B2 (ja) | ピリジン置換の２−アミノピリジン類タンパク質キナーゼ阻害剤 | |
| EP3181554B1 (en) | Quinazoline derivative | |
| CN107827875B (zh) | 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用 | |
| JPWO2008139894A1 (ja) | 含窒素芳香族６員環誘導体並びにそれらを含む医薬 | |
| CN103476769B (zh) | 抗癌剂 | |
| US20130131112A1 (en) | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof | |
| JP2023551116A (ja) | 治療薬としてのコハク酸塩及びその結晶形 | |
| US7888380B2 (en) | 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives | |
| CN115716850B (zh) | 芳基磷氧化合物的晶型、制备方法及用途 | |
| CN114790177B (zh) | 新型Hedgehog信号通路抑制剂 | |
| EP2426130B1 (en) | Purine derivative and antitumor agent using same | |
| WO2026055156A1 (en) | Rock2 inhibitors and uses thereof |